순환 무세포 종양 DNA 시장 : 종양 유형별, 암 유형별, 기술별, 용도별, 지역별 - 시장 규모, 점유율, 전망 및 기회 분석(2023-2030년)

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

• This report provides an in-depth analysis of the global circulating cell-free tumor DNA market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

• Global Circulating Cell-Free Tumor DNA Market, By Tumor Type:
  • Malignant Tumors
  • Precancerous Tumors
• Global Circulating Cell-Free Tumor DNA Market, By Cancer Type:
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Others
• Global Circulating Cell-Free Tumor DNA Market, By Technology:
  • PCR
  • Massively Parallel Sequencing
  • Single Nucleotide Polymorphism
• Global Circulating Cell-Free Tumor DNA Market, By Application:
  • Cancer Diagnosis
  • Targeting Therapeutics
  • Prognosis Indication
• Global Circulating Cell-Free Tumor DNA Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Biocept, Inc.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Illumina, Inc.
  • Quest Diagnostics Incorporated
  • KURABO INDUSTRIES LTD
  • PerkinElmer chemagen Technologie GmbH
  • Biodesix
  • Guardant Health
  • QIAGEN
  • Sequenom, Inc.
  • Agilent Technologies, Inc.
  • Fluxion Biosciences Inc.
  • Natera, Inc.
  • Agena Bioscience, Inc.
  • Paragon Genomics, Inc.
  • Lucence Health Inc.
  • Eurofins Genomics
  • Thermo Fisher Scientific

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Tumor Type
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By Technology
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Highlights
• Product Launch
• Technological Advancements
• PEST Analysis
• Regulatory Scenario
• Mergers and Acquisitions

4. Global Circulating Cell-free Tumor DNA Market- COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2018 - 2030, (US$ Billion)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Malignant Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Precancerous Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

6. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2018 - 2030, (US$ Billion)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segments Trends
• Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Colorectal Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Breast Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

7. Global Circulating Cell-free Tumor DNA Market, By Technology, 2018 - 2030, (US$ Billion)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segments Trends
• PCR
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Massively Parallel Sequencing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Single Nucleotide Polymorphism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Global Circulating Cell-free Tumor DNA Market, By Application, 2018 - 2030, (US$ Billion)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Cancer Diagnosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Targeting Therapeutics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
• Prognosis Indication
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

9. Global Circulating Cell-free Tumor DNA Market, By Region, 2018 - 2030, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 - 2030, (US$ Billion)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Biocept, Inc.*
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Illumina, Inc.
• Quest Diagnostics Incorporated
• KURABO INDUSTRIES LTD
• PerkinElmer chemagen Technologie GmbH
• Biodesix
• Guardant Health
• QIAGEN
• Sequenom, Inc.
• Agilent Technologies, Inc.
• Fluxion Biosciences Inc.
• Natera, Inc.
• Agena Bioscience, Inc.
• Paragon Genomics, Inc.
• Lucence Health Inc.
• Eurofins Genomics
• Thermo Fisher Scientific

11. Section

• Research Methodology
• About Us